山西大便连续出血山西痔疮很痛怎么办,山西拉大便拉出血,山西肛肠吻合,太原肛门周围脓肿咨询,山西肛肠医院粒肠,山西拉血便怎么回事,山西痔疮的症状

JIANGYIN, Jiangsu, July 1 (Xinhua) -- China's manned deep-diving submersible, the Jiaolong, embarked on a journey on Friday during which it will make a 5,000-meter dive in the Pacific Ocean.During the dive, the submersible will undergo several operational tests in which it will take photos, shoot video, survey seabeds and take samples from the ocean floor, according to Jin Jiancai, deputy director of the submersible's diving test program team.The tests will be conducted in the Pacific Ocean in accordance with a contract signed between the China Ocean Mineral Resources Research & Development Association and the International Seabed Authority (ISA).The submersible is scheduled to spend 47 days at sea, according to a statement from the Ministry of Science and Technology.A submersible differs from a submarine, as it typically depends on another vessel or facility for support.The Jiaolong, designed to reach a depth of 7,000 meters, completed 17 dives in the South China Sea between May 31 and July 18 last year, reaching 3,759 meters during its deepest dive.In the year since the submersible's last dive, program team members have made several technical improvements to the submersible and its support vessel, Jin said.Jin said the program team members are "very confident" about the test.He also stressed that the test will be carried out in accordance with the provisions of the United Nations Convention on the Law of the Sea as well as the ISA's rules and regulations.The Jiaolong is the world's first manned submersible designed to reach depths of 7,000 meters below sea level, according to Xu Qinan, the submersible's chief designer.

SAN FRANCISCO, July 29 (Xinhua) -- Apple has ousted Nokia as the world's largest smartphone maker as global mobile phone market grew more than 11.3 percent in the second quarter of 2011, according to two separate market research studies.After becoming the largest smartphone vendor in terms of revenue and profits, Apple has become the world's largest smartphone vendor by volume with 18.5 percent market share, said the latest research from Strategy Analytics released on Friday.The Cupertino, California-based company sold 20.3 million iPhones in the second quarter,up 142 percent compared with the same period a year earlier.Samsung's shipments of 19.2 million units grew a huge 520 percent year over year, accounting for 17.5 percent global smartphone market share in the second quarter of 2011.Apple and Samsung overtook long-time volume leader Nokia for the two spots. The Finnish mobile phone giant accounted for 15.2 percent of global smartphone market share in the last quarter, which is less than half of what it was just one year earlier.In the second quarter of 2010, Nokia was the No.1 smartphone maker by volume in the world with 38.1 percent of market share. The industry is now waiting Nokia's pending transition to Windows Phone 7.According to a separate report by International Data Corporation (IDC) released on Thursday, the worldwide mobile phone market grew by 11.3 percent year over year in the second quarter of 2011 despite a decline of the feature phone market for the first time in almost two years.The feature phone market was down by 4 percent in the last quarter, said the IDC Worldwide Mobile Phone Tracker report. It noted that the decline in shipments was mainly in economically mature regions, such as the United States, Japan and Western Europe, as users making rapid transition to smartphones.The shrinking feature phone market had a great impact on some of the world's largest suppliers of mobile phones, such as Nokia, which is losing share in the feature phone category to low-cost suppliers, said the report.For the overall market, global mobile phone vendors shipped 365. 4 million units in the second quarter, compared to 328.4 million units in the same period last year, with Nokia still holding the top spot with a market share of 24.2 percent, followed by Samsung, LG Electronics, Apple and ZTE.But the 11.3 percent growth was lower than IDC's forecast for the quarter and also below the 16.8 percent growth in the first quarter of 2011.IDC said the feature phone forecast isn't expected to be any rosier in the future and the shipment growth of feature phones won 't exceed 1.1 percent in the coming years.

SYDNEY, July 15 (Xinhua) -- The world's first drug to increase life expectancy of people with advanced melanoma has been approved for use in Australia, local media reported on Friday.The breakthrough drug Yervoy got approval from the Therapeutics Good Association (TGA) on Friday amid hopes it could add two years to the life of people with the most lethal form of skin cancer but for whom other treatments have failed, the Australian Associated Press (AAP) said.Clearance for the drug's use in Australia follows similar approvals by the U.S. health regulator in March.Yervoy works by attacking and destroying cancer cells.Patients are hooked up to an intravenous drip once every three weeks for a total of four doses.Professor Peter Hersey, consultant immunologist to the Melanoma Institute Australia, said no other drug had improved survival rates like Yervoy."Not all patients respond to it but those who do have a good chance of living longer than they would have otherwise," Hersey told AAP.While it may improve survival rates, Yervoy can produce side effects from diarrhea and vomiting to serious blood infections and kidney failure.The average survival time for people with advanced melanoma is just six months.A global study of 676 people with melanoma found that 45 percent of patients given Yervoy were still alive after one year, according to AAP.More than 20 percent lived at least two years, with a small number managing to survive for six years.A separate study, published in June, which showed similarly improved survival rates for patients with newly diagnosed advanced melanoma, has raised hopes that Yervoy could be made more widely available.Melanoma is the fourth most common cancer in Australia, with 10, 300 people diagnosed each year.

WASHINGTON, Aug. 2 (Xinhua) -- A new study has identified the recent emergence of a multidrug-resistant strain of Salmonella that has a high level resistance to ciprofloxacin, a common treatment for severe Salmonella infections. The study was published on-line Tuesday in The Journal of Infectious Diseases.Francois-Xavier Weill at the Pasteur Institute in France and colleagues studied information from national surveillance systems in France, England and Wales, Denmark, and the United States. The data showed that a multidrug-resistant strain of Salmonella, known as S. Kentucky, infected 489 patients in France, England and Wales, and Denmark between 2000 and 2008. In addition, researchers reported that the first infections were acquired mainly in Egypt between 2002 and 2005, while since 2006 the infections have also been acquired in various parts of Africa and the Middle East. The absence of reported international travel in approximately 10 percent of the patients suggests that infections may have also occurred in Europe through consumption of contaminated imported foods or through secondary contaminations.In this study, multidrug-resistant S. Kentucky was isolated from chickens and turkeys from Ethiopia, Morocco, and Nigeria, suggesting that poultry is an important agent for infection. The common use of fluoroquinolones in chicken and turkey production in Nigeria and Morocco may have contributed to this rapid spread, according to the researchers.This study highlights the importance of public health surveillance in a global food system. The investigators reported that they will continue to monitor this multidrug-resistant strain as well as help strengthen the capacities of national and regional laboratories in the surveillance of Salmonella and other major foodborne pathogens through the World Health Organization Global Foodborne Infections Network.Salmonella infection represents a major public health problem worldwide. An estimated 1.7 million such infections occur in North America each year. More than 1.6 million cases were reported between 1999 and 2008 in 27 European countries. Although most Salmonella infections produce only mild gastroenteritis, elderly and immunocompromised patients are especially at risk for life- threatening infections. These cases are typically treated with antimicrobials called fluoroquinolones, such as ciprofloxacin.

SAN FRANCISCO, June 22 (Xinhua) -- Apple Inc. plans to introduce a new iPhone in September featuring faster chip and more advanced camera, U.S. media reported on Wednesday.The new iPhone model, which will closely resemble iPhone 4, will include the A5 processor, a more powerful chip that Apple added to the iPad 2 tablet computer earlier this year, along with an 8-megapixel camera, up from the 5-megapixel model in the iPhone 4, Bloomberg quoted two people familiar with the product as saying.The device will run the iOS 5 operating system Apple previewed at its annual developer conference earlier this month.Aiming at attracting customers in developing countries, Apple is also working to finish a cheaper version of the iPhone which will use chips and displays of similar quality to the current iPhone 4, said the sources.Meanwhile, it was reported that Apple is also testing a new version of the iPad with a higher resolution screen, which, similar to the one currently used on iPhone 4, will be about one- third higher than iPad 2 and feature a more responsive touchscreen.According to a recent projection on smartphone market by the International Data Corp. (IDC), a small market share decline of iPhone is expected as the smartphone market matures and diversifies in 2011.The release of a new iPhone would help Apple gain more market share as smartphones powered by Google's Android system are predicted to grow to more than 40 percent of the market in the second half of this year.